CYCN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.200

Open

3.160

VWAP

2.97

Vol

327.42K

Mkt Cap

13.68M

Low

2.800

Amount

973.54K

EV/EBITDA(TTM)

--

Total Shares

4.33M

EV

10.44M

EV/OCF(TTM)

--

P/S(TTM)

4.82

Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

Show More

Events Timeline

(ET)

2026-04-01

07:10:00

Cyclerion and Korsana Enter Merger Agreement

2026-02-17 (ET)

2026-02-17

07:20:00

Cyclerion Receives Positive FDA Feedback on CYC-126

2026-01-05 (ET)

2026-01-05

16:10:00

Cyclerion Announces Exclusive Collaboration with Medsteer

2025-12-22 (ET)

2025-12-22

16:50:00

Cycurion Files to Sell 4.97M Shares of Common Stock for Holders

2025-09-23 (ET)

2025-09-23

16:08:20

Cyclerion Signs Licensing Deal with MIT and Unveils Strategic Relaunch

2025-05-06 (ET)

2025-05-06

16:59:34

Cyclerion Therapeutics files to sell 500K shares of common stock for holders

2024-12-17 (ET)

2024-12-17

07:20:51

Cyclerion Therapeutics announces update on next stage of growth

News

PRnewswire

04-09PRnewswire

Investor Rights Law Firm Investigates Multiple Companies for Potential Violations

Globenewswire

04-09Globenewswire

Investigation Alerts for Multiple Company Mergers

Globenewswire

04-07Globenewswire

Investor Rights Law Firm Investigates Multiple Companies for Potential Violations

Globenewswire

04-03Globenewswire

Investor Rights Law Firm Investigates Multiple Companies for Potential Violations

PRnewswire

04-01PRnewswire

Investigation Launched into Cyclerion's Transaction with Korsana

seekingalpha

04-01seekingalpha

U.S. March Manufacturing PMI Slightly Rises

Valuation Metrics

The current forward P/E ratio for Cyclerion Therapeutics Inc (CYCN.O) is 0.00, compared to its 5-year average forward P/E of -0.60. For a more detailed relative valuation and DCF analysis to assess Cyclerion Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.60

Current PE

0.00

Overvalued PE

0.17

Undervalued PE

-1.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.10

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.27

Undervalued EV/EBITDA

-0.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

7.88

Current PS

0.00

Overvalued PS

20.67

Undervalued PS

-4.92

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

top penny stocks to buy today

Intellectia · 146 candidates

Price: $0.10 - $5.00Rsi Category: moderateRelative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Predict Return: >= 0.0%Monthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

Xiao-I Corp

26.23M

Virgin Galactic Holdings Inc

241.78M

ThredUp Inc

482.44M

OFS Credit Company Inc

85.23M

Spero Therapeutics Inc

157.46M

Brazil Potash Corp

181.76M

THERE IS A DAY TRADING SIGNAL

Intellectia · 21 candidates

Rsi Category: moderate, overboughtPrice Change Pct: $3.00 - $15.00Relative Vol: >= 2Support Resistance Relationship: PriceBreakResistanceThree Min Rate Of Change: >= 0.5%

Ticker

Name

Market Cap$

Taoping Inc

11.92M

Jinxin Technology Holding Co

42.62M

Ovid Therapeutics Inc

303.31M

Intelligent Group Ltd

10.84M

Lakeside Holdings Ltd

29.99M

CapsoVision Inc

289.49M

create swing trade setup

Intellectia · 358 candidates

Price: $1.00 - $5.00List Exchange: XNAS, XNYS, XASEMoving Average Relationship: PriceAboveMA20, PriceBelowMA5, PriceBelowMA10Week Price Change Pct: $-10.00 - $10.00Macd: bullish, positive

Ticker

Name

Market Cap$

Alaunos Therapeutics Inc

7.60M

OS Therapies Inc

53.17M

Nano-X Imaging Ltd

169.34M

Fluent Inc

107.58M

Lexicon Pharmaceuticals Inc

685.30M

Marti Technologies Inc

175.91M

Whales Holding CYCN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Cyclerion Therapeutics Inc (CYCN) stock price today?

The current price of CYCN is 2.92 USD — it has decreased -7.59

What is Cyclerion Therapeutics Inc (CYCN)'s business?

Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

What is the price predicton of CYCN Stock?

Wall Street analysts forecast CYCN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYCN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cyclerion Therapeutics Inc (CYCN)'s revenue for the last quarter?

Cyclerion Therapeutics Inc revenue for the last quarter amounts to 1.02M USD, decreased -43.24

What is Cyclerion Therapeutics Inc (CYCN)'s earnings per share (EPS) for the last quarter?

Cyclerion Therapeutics Inc. EPS for the last quarter amounts to -0.21 USD, decreased -200.00

How many employees does Cyclerion Therapeutics Inc (CYCN). have?

Cyclerion Therapeutics Inc (CYCN) has 1 emplpoyees as of April 10 2026.

What is Cyclerion Therapeutics Inc (CYCN) market cap?

Today CYCN has the market capitalization of 13.68M USD.